Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Exclusion Criteria

• •1. Follicular lymphoma Grade 3b
• •2. History of allergy to any of the study medications, their analogues, murine proteins, or excipients in the various formulations
• •3. Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment
• •4. Serum creatinine 2.5 mg/dL within 14 days before enrollment.
• •5. Absolute neutrophil count (ANC) \< 1,000/L, platelet count \< 70,000/L within 14 days before enrollment
• •6. Aspartate transaminase (AST \[SGOT\]) and alanine transaminase (ALT/SGPT\]) \> 2 x the upper limit of normal (ULN), total bilirubin \> 3 ULN
• •7. Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6 months)
• •8. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosurea or mytomycin-C)
• •9. Prior lymphoma vaccine therapy within 12 months to Study Day 1
• •10. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1
• •11. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1
• •12. Known history of hepatitis or hepatic disease.
• •13. Presence of central nervous system (CNS) lymphoma
• •14. Known history of HIV infection or AIDS
• •15. Histologic transformation (Follicular or Marginal zone to diffuse large B cell lymphoma \[DLBCL\]
• •16. Presence of pleural or peritoneal effusion with positive cytology for lymphoma
• •17. Another primary malignancy requiring active treatment
• •18. Serious non-malignant disease (e.g., congestive heart failure \[CHF\], hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions (including psychiatric), which would compromise protocol objectives n the opinion of the Investigator and/or Sponsor
• •19. New York Heart Association Class III or IV (Appendix D) cardiac disease
• •20. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
• •21. Female subject who is pregnant or currently breast-feeding
• •22. Received other investigational drugs with 14 days before enrollment
• •23. Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.